Companies / Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc.
Nasdaq: LXEOCIK 1907108NEW YORK, NY
Financials · FY2023
Ownership
82.0M shares outstanding · as of Aug 10, 2026
Ownership
| Insiders | 0.81% | 665,661 |
| 10%+ / strategic | 11.26% | 9,240,589 |
| Institutions | 84.62% | 69,427,913 |
| Public float | 3.31% | 2,712,092 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 6
View all →| Insider | % of shares | Shares |
|---|---|---|
Townsend Richard NolanCEOChief Executive Officer · Director | 0.48% | 395,106 |
Otero Jose ManuelChief Operating Officer | 0.16% | 131,390 |
Tamayo Louis EdwardChief Financial Officer | 0.11% | 89,665 |
Bhalla Narinder PalChief Medical Officer | 0.06% | 49,500 |
Cholmondeley Paula HDirector | — | — |
Diaz Reinaldo MDirector | — | — |
Institutional holders 146
View all →| Holder | Value | % of shares |
|---|---|---|
| $47.30M | 5.81% | |
| $44.44M | 5.45% | |
| $43.94M | 5.39% | |
| $38.67M | 4.75% | |
| $37.48M | 4.60% | |
| $32.77M | 4.02% | |
| $31.78M | 3.90% | |
| $31.75M | 3.90% | |
| $28.70M | 6.09% | |
| $28.51M | 6.07% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Add | Common stock | $8.48M | +1.5M +69.53% | 3,602,450 4.39% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $5.43M | +1.2M +36.61% | 4,354,757 5.31% of shares | medium |
| Q1 2026 as of | Blackstone Inc 13F manager | New | Common stock | $5.19M | +905K | 904,959 1.10% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common stock | $4.05M | +705K +77.61% | 1,612,780 1.97% of shares | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $3.87M | +832K +16.95% | 5,739,455 7.00% of shares | low |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Trim | Common stock | $-3.05M | -533K -9.68% | 4,976,429 6.07% of shares | low |
| Q1 2026 as of | D. E. Shaw & Co., Inc. 13F manager | Trim | Common stock | $-2.58M | -450K -93.65% | 30,477 0.04% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Exit | Common stock | $-2.16M | -218K -100.00% | 0 | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| State Street Corporation | Passive13G | — |
| Vanguard Group Inc | Passive13G/A | — |
| Vanguard Group Inc | Passive13G | — |
| Balyasny Asset Management L.P. | Passive13G/A | — |
| Citadel Advisors LLC | Passive13G/A | — |
| Affinity Asset Advisors, LLC | Passive13G/A | — |
| Paradigm BioCapital Advisors LP | Passive13G/A | — |
| Frazier Life Sciences Public Fund, L.P. | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| LXEO | — | 52886X107 |